A detailed history of D. E. Shaw & Co., Inc. transactions in Myriad Genetics Inc stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 1,126,747 shares of MYGN stock, worth $29.8 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
1,126,747
Previous 1,266,113 11.01%
Holding current value
$29.8 Million
Previous $27 Million 2.1%
% of portfolio
0.03%
Previous 0.02%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$17.98 - $25.47 $2.51 Million - $3.55 Million
-139,366 Reduced 11.01%
1,126,747 $27.6 Million
Q1 2024

May 15, 2024

SELL
$17.59 - $23.59 $9.41 Million - $12.6 Million
-535,193 Reduced 29.71%
1,266,113 $27 Million
Q4 2023

Feb 14, 2024

SELL
$13.91 - $21.32 $5.24 Million - $8.03 Million
-376,619 Reduced 17.29%
1,801,306 $34.5 Million
Q3 2023

Nov 14, 2023

BUY
$15.99 - $23.22 $2.41 Million - $3.5 Million
150,903 Added 7.44%
2,177,925 $34.9 Million
Q2 2023

Aug 14, 2023

BUY
$17.56 - $23.76 $784,879 - $1.06 Million
44,697 Added 2.25%
2,027,022 $47 Million
Q1 2023

May 15, 2023

BUY
$15.26 - $23.75 $1.91 Million - $2.97 Million
125,025 Added 6.73%
1,982,325 $46 Million
Q4 2022

Feb 14, 2023

BUY
$14.51 - $20.99 $1.46 Million - $2.12 Million
100,834 Added 5.74%
1,857,300 $26.9 Million
Q3 2022

Nov 14, 2022

SELL
$18.21 - $27.88 $5.18 Million - $7.93 Million
-284,394 Reduced 13.94%
1,756,466 $33.5 Million
Q2 2022

Aug 15, 2022

BUY
$16.45 - $25.88 $2.54 Million - $3.99 Million
154,286 Added 8.18%
2,040,860 $37.1 Million
Q1 2022

May 16, 2022

SELL
$22.67 - $28.01 $476,750 - $589,050
-21,030 Reduced 1.1%
1,886,574 $47.5 Million
Q4 2021

Feb 14, 2022

SELL
$24.13 - $32.63 $2.44 Million - $3.3 Million
-101,258 Reduced 5.04%
1,907,604 $52.7 Million
Q3 2021

Nov 15, 2021

SELL
$29.97 - $36.66 $7.01 Million - $8.57 Million
-233,807 Reduced 10.43%
2,008,862 $64.9 Million
Q2 2021

Aug 16, 2021

SELL
$25.39 - $32.61 $10.6 Million - $13.6 Million
-417,038 Reduced 15.68%
2,242,669 $68.6 Million
Q1 2021

May 17, 2021

SELL
$19.92 - $31.6 $11.1 Million - $17.6 Million
-555,742 Reduced 17.28%
2,659,707 $81 Million
Q4 2020

Feb 16, 2021

SELL
$12.16 - $19.77 $2.41 Million - $3.91 Million
-197,964 Reduced 5.8%
3,215,449 $63.6 Million
Q3 2020

Nov 16, 2020

BUY
$11.25 - $14.75 $1.4 Million - $1.83 Million
124,083 Added 3.77%
3,413,413 $44.5 Million
Q2 2020

Aug 14, 2020

BUY
$10.69 - $16.49 $6.51 Million - $10 Million
609,172 Added 22.73%
3,289,330 $37.3 Million
Q1 2020

May 15, 2020

SELL
$9.78 - $29.53 $1.84 Million - $5.56 Million
-188,256 Reduced 6.56%
2,680,158 $38.4 Million
Q4 2019

Feb 14, 2020

BUY
$20.93 - $35.1 $7.63 Million - $12.8 Million
364,645 Added 14.56%
2,868,414 $78.1 Million
Q3 2019

Nov 14, 2019

SELL
$22.08 - $47.08 $18.1 Million - $38.6 Million
-819,327 Reduced 24.66%
2,503,769 $71.7 Million
Q2 2019

Aug 14, 2019

SELL
$22.67 - $35.0 $11.9 Million - $18.3 Million
-523,346 Reduced 13.61%
3,323,096 $92.3 Million
Q1 2019

May 15, 2019

SELL
$26.93 - $34.7 $2.06 Million - $2.65 Million
-76,410 Reduced 1.95%
3,846,442 $128 Million
Q4 2018

Feb 14, 2019

BUY
$27.23 - $45.56 $813,469 - $1.36 Million
29,874 Added 0.77%
3,922,852 $114 Million
Q3 2018

Nov 14, 2018

SELL
$37.57 - $50.34 $5.93 Million - $7.94 Million
-157,755 Reduced 3.89%
3,892,978 $179 Million
Q2 2018

Aug 14, 2018

SELL
$27.75 - $40.17 $3.68 Million - $5.33 Million
-132,682 Reduced 3.17%
4,050,733 $151 Million
Q1 2018

May 15, 2018

SELL
$28.83 - $41.01 $16.5 Million - $23.5 Million
-573,174 Reduced 12.05%
4,183,415 $124 Million
Q4 2017

Feb 14, 2018

SELL
$28.45 - $37.14 $3.11 Million - $4.06 Million
-109,314 Reduced 2.25%
4,756,589 $163 Million
Q3 2017

Nov 14, 2017

BUY
$24.01 - $36.2 $117 Million - $176 Million
4,865,903
4,865,903 $176 Million

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $2.13B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.